SG11201603091QA - Ferric citrate for reducing cardiac failure in chronic kidney disease patients - Google Patents
Ferric citrate for reducing cardiac failure in chronic kidney disease patientsInfo
- Publication number
- SG11201603091QA SG11201603091QA SG11201603091QA SG11201603091QA SG11201603091QA SG 11201603091Q A SG11201603091Q A SG 11201603091QA SG 11201603091Q A SG11201603091Q A SG 11201603091QA SG 11201603091Q A SG11201603091Q A SG 11201603091QA SG 11201603091Q A SG11201603091Q A SG 11201603091QA
- Authority
- SG
- Singapore
- Prior art keywords
- kidney disease
- chronic kidney
- disease patients
- ferric citrate
- cardiac failure
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title 1
- 208000020832 chronic kidney disease Diseases 0.000 title 1
- 229960002413 ferric citrate Drugs 0.000 title 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899866P | 2013-11-04 | 2013-11-04 | |
| PCT/US2014/063643 WO2015066593A1 (en) | 2013-11-04 | 2014-11-03 | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201603091QA true SG11201603091QA (en) | 2016-05-30 |
Family
ID=53005244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201603091QA SG11201603091QA (en) | 2013-11-04 | 2014-11-03 | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20160256486A1 (en) |
| EP (2) | EP3065734A4 (en) |
| JP (3) | JP2016535780A (en) |
| KR (1) | KR102392441B1 (en) |
| CN (1) | CN105873583A (en) |
| AU (1) | AU2014341975A1 (en) |
| BR (1) | BR112016009901A8 (en) |
| CA (1) | CA2928200A1 (en) |
| EA (1) | EA201690926A1 (en) |
| HK (1) | HK1223031A1 (en) |
| IL (1) | IL245317A0 (en) |
| MX (1) | MX2016005734A (en) |
| SG (1) | SG11201603091QA (en) |
| TW (2) | TW202203910A (en) |
| WO (1) | WO2015066593A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012000892A (en) | 2009-07-21 | 2012-06-01 | Keryx Biopharmaceuticals Inc | Ferric citrate dosage forms. |
| ES2646271T3 (en) | 2013-06-05 | 2017-12-13 | Tricida Inc. | Proton binding polymers for oral administration |
| EP3157516A4 (en) | 2014-06-22 | 2017-12-13 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| MD3229816T2 (en) | 2014-12-10 | 2020-07-31 | Tricida Inc | Proton-binding polymers for oral administration |
| IL262660B2 (en) | 2016-05-06 | 2024-04-01 | Tricida Inc | Preparations for and method of treating acid-base disorders |
| CA3080651A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| MX2021004640A (en) * | 2018-10-29 | 2021-05-28 | Pharmacosmos Holding As | Treating iron deficiency with ferric carboxymaltose. |
| CN114286682A (en) * | 2019-02-09 | 2022-04-05 | 法码科思莫斯控股有限公司 | Treatment of iron deficiency in individuals at risk for adverse cardiovascular events and iron for the treatment of atrial fibrillation |
| TW202313072A (en) * | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | Pediatric formulations of ferric citrate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE351366B (en) * | 1965-06-08 | 1972-11-27 | Teikoku Hormone Mfg Co Ltd | |
| US20050203169A1 (en) * | 2001-08-06 | 2005-09-15 | Moskowitz David W. | Methods and compositions for treating diseases associated with excesses in ACE |
| US8093423B2 (en) * | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| JP5667343B2 (en) * | 2005-08-18 | 2015-02-12 | パニオン アンド ビーエフ バイオテック インコーポレーテッド | Pharmaceutical grade ferric organic compounds, their use and process for their production |
| KR20080094013A (en) * | 2006-01-30 | 2008-10-22 | 글로보아시아 엘엘씨 | How to reverse, prevent, delay or stabilize calcification of soft tissues |
| EP3066923A3 (en) | 2006-01-30 | 2016-10-19 | Panion & BF Biotech Inc. | Method of treating chronic kidney disease |
| MX2012000892A (en) * | 2009-07-21 | 2012-06-01 | Keryx Biopharmaceuticals Inc | Ferric citrate dosage forms. |
| JP5827326B2 (en) * | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | Compounds and methods for inhibiting phosphate transport |
| PL3730136T3 (en) * | 2012-06-21 | 2024-03-25 | Keryx Biopharmaceuticals, Inc. | Use of ferric citrate in the treatment of chronic kidney disease patients |
-
2014
- 2014-11-03 BR BR112016009901A patent/BR112016009901A8/en not_active Application Discontinuation
- 2014-11-03 WO PCT/US2014/063643 patent/WO2015066593A1/en active Application Filing
- 2014-11-03 SG SG11201603091QA patent/SG11201603091QA/en unknown
- 2014-11-03 CN CN201480072217.1A patent/CN105873583A/en active Pending
- 2014-11-03 AU AU2014341975A patent/AU2014341975A1/en not_active Abandoned
- 2014-11-03 JP JP2016552432A patent/JP2016535780A/en active Pending
- 2014-11-03 EA EA201690926A patent/EA201690926A1/en unknown
- 2014-11-03 KR KR1020167014000A patent/KR102392441B1/en active Active
- 2014-11-03 CA CA2928200A patent/CA2928200A1/en not_active Abandoned
- 2014-11-03 EP EP14858106.9A patent/EP3065734A4/en not_active Ceased
- 2014-11-03 EP EP20173867.1A patent/EP3747432A1/en active Pending
- 2014-11-03 US US15/031,678 patent/US20160256486A1/en not_active Abandoned
- 2014-11-03 HK HK16111332.6A patent/HK1223031A1/en unknown
- 2014-11-04 TW TW110136784A patent/TW202203910A/en unknown
- 2014-11-04 TW TW103138244A patent/TWI744215B/en active
-
2015
- 2015-01-29 MX MX2016005734A patent/MX2016005734A/en unknown
-
2016
- 2016-04-27 IL IL245317A patent/IL245317A0/en unknown
-
2018
- 2018-12-11 US US16/216,772 patent/US20190307791A1/en not_active Abandoned
-
2019
- 2019-07-31 JP JP2019140640A patent/JP6828100B2/en active Active
-
2021
- 2021-01-20 JP JP2021007091A patent/JP2021073230A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016535780A (en) | 2016-11-17 |
| CN105873583A (en) | 2016-08-17 |
| EP3747432A1 (en) | 2020-12-09 |
| AU2014341975A1 (en) | 2016-05-19 |
| HK1223031A1 (en) | 2017-07-21 |
| TW201609088A (en) | 2016-03-16 |
| KR20160096597A (en) | 2016-08-16 |
| BR112016009901A8 (en) | 2020-04-14 |
| US20190307791A1 (en) | 2019-10-10 |
| JP2021073230A (en) | 2021-05-13 |
| KR102392441B1 (en) | 2022-05-02 |
| WO2015066593A1 (en) | 2015-05-07 |
| JP6828100B2 (en) | 2021-02-10 |
| EP3065734A4 (en) | 2017-05-17 |
| CA2928200A1 (en) | 2015-05-07 |
| MX2016005734A (en) | 2016-11-08 |
| JP2019206562A (en) | 2019-12-05 |
| US20160256486A1 (en) | 2016-09-08 |
| TWI744215B (en) | 2021-11-01 |
| TW202203910A (en) | 2022-02-01 |
| EP3065734A1 (en) | 2016-09-14 |
| IL245317A0 (en) | 2016-06-30 |
| EA201690926A1 (en) | 2016-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245317A0 (en) | Ferric citrate for reducing cardiac failure in chronic kidney disease patients | |
| IL236356A0 (en) | Use of ferric citrate in the treatment of chronic kidney disease patients | |
| EP3862044C0 (en) | Dual-tip hemodialysis catheter | |
| GB2585392B (en) | System and method for performing alternative and sequential blood and peritoneal dialysis modalities | |
| IL242804B (en) | Pridopidine for use in reducing impairment of functional capacity in huntington disease patients | |
| IL245211A0 (en) | Medicament inhaler | |
| AU353287S (en) | Patient interface | |
| AU353289S (en) | Patient interface | |
| ZA201501977B (en) | Orally administered medical composition | |
| EP2833957A4 (en) | Therapy for kidney disease and/or heart failure by intradermal infusion | |
| GB201314512D0 (en) | Dual Haemodialysis and Haemodiafiltration blood treatment device | |
| EP2990040A4 (en) | Therapeutic agent for eyeground disease | |
| SG11201601490XA (en) | Risk markers for cardiovascular disease in patients with chronic kidney disease | |
| LT2958624T (en) | TREATMENT OF TRANSPLANTANT DISEASE IN TRANSPLANTANT PATIENTS | |
| IL240218A0 (en) | Catheter for denervation | |
| PL2875049T3 (en) | Methods for preventing and treating chronic kidney disease (ckd) | |
| EP2959908A4 (en) | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease | |
| EP2959905A4 (en) | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease | |
| EP2959906A4 (en) | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease | |
| GB201305758D0 (en) | Blood Pump | |
| GB201305761D0 (en) | Blood Pump | |
| EP3217987A4 (en) | Sglt-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | |
| EP2959907A4 (en) | Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease | |
| RS57172B1 (en) | Compositions for use in the treatment of dyslipidaemia in chronic kidney disease | |
| PL2849835T3 (en) | A non-temporary central venous catheter for use in haemodialysis |